🇺🇸 US

AXSM revenue, net income and debt history (Axsome Therapeutics, Inc.)

Quick answer

Axsome Therapeutics, Inc. (AXSM) reported revenue of $638.5M and net loss of $183.2M for the fiscal year ended 2025-12-31, up 65.5% from $385.7M the year before, per its 10-K filed with the SEC on 2026-02-23. Long-term debt stood at $117.7M.

✓ SEC EDGAR XBRL company facts (10-K/10-Q filings)

Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)

Fiscal yearRevenueNet incomeLong-term debt
2025 (FY ending 2025-12-31)$638.5M-$183.2M$117.7M
2024 (FY ending 2024-12-31)$385.7M-$287.2M$180.7M
2023 (FY ending 2023-12-31)$270.6M-$239.2M$178.1M
2022 (FY ending 2022-12-31)$0.0M-$187.1M$94.3M
2021 (FY ending 2021-12-31)—-$130.4M$49.1M
2020 (FY ending 2020-12-31)—-$102.9M$48.3M
2019 (FY ending 2019-12-31)—-$68.3M$17.3M
2018 (FY ending 2018-12-31)—-$31.0M$3.6M
2017 (FY ending 2017-12-31)—-$28.9M$6.7M
2016 (FY ending 2016-12-31)—-$27.2M$9.5M

Related

Last updated 2026-10-16. Data only, not financial or tax advice.